Reta~trutide
Reta~trutide
Other recommendations
Quantity
Minimum order is: 2 boxsShipping
Supplier will ship within 3–10 days of confirmed payment.
Goods will be dispatched from United Kingdom, China port.
Shipping is offered under FOB terms — the supplier covers costs to the named port of shipment.
Payment: Western Union
Sample available · $300.00/sample
Euromart Suppliers order protection
Every payment you make is secured with strict SSL encryption and PCI DSS data protection protocols
Make free local returns for defects on qualifying purchases
Claim a refund if your order doesn't ship, is missing, or arrives with product issues
Meet your supplier
Distributor / Wholesaler • 3 yr • 
UNITED KINGDOM
56%
On-time delivery rate
≤24h
Response Time
75
Employee Size
$500K
Annual Revenue
588
Products Sold
Location
Belfast, United Kingdom
Other recommendations
KEY FEATURES
Therapeutic Class: Investigational peptide therapy
Mechanism of Action: Triple receptor agonist (GIP, GLP‑1, glucagon)
Primary Uses (Investigational): Obesity management, metabolic regulation, type 2 diabetes (under study)
Clinical Benefits (Trial Data):
Up to 24–25% body weight reduction in <1 year
Improved glucose metabolism and insulin sensitivity
Appetite suppression and increased energy expenditure
Status: Not FDA‑approved; currently in Phase II/III clinical trials
TECHNICAL SPECIFICATIONS
Molecular Type: Synthetic peptide (LY‑3437943)
Administration Route: Subcutaneous injection (once weekly)
Formulation: Prefilled injection pens (trial use)
Stability & Storage: Refrigerated until use; stability data under investigation
Safety Profile (Investigational):
GI side effects (nausea, diarrhea)
Risks under study: bone health, kidney complications, rapid weight loss
Regulatory Identifiers: Not yet assigned ATC code or HS classification (pending approval)
AVAILABLE CONFIGURATIONS
Format & Delivery:
Prefilled injection pens (trial formulations)
Bulk API (research supply only)
Concentration & Dosing:
Investigational fixed strengths (dose escalation in trials)
No commercial dosing yet established
Packaging & Labeling:
Clinical trial packaging only
Future potential: finished product packaging, private labeling (post‑approval)
Ratings & Reviews
From Other Suppliers
Ozempic 2 Pens 0.25mg + 0.5mg Wholesale & Retail in Europe, UK, USA, Asia
MOQ: 8 pieces71 sold
USOzempic Injection – Semaglutide Injection 025mg 0.5mg 1mg, 1 Pen
MOQ: 10 pieces31 sold
USOzempic Pens 0.25mg Wholesale & Retail in Europe, UK, USA, Asia
MOQ: 6 pieces39 sold
US
GB
